Join
Live feed
·
PRReleasevia Quantisnow
Guardant Health Inc. logo

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
GH· Guardant Health Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GH (Guardant Health Inc.) and more on Quantisnow.